Bank of America Corporation (BAC) is a diversified U.S. bank, not an ETF. After its Q3 2026 earnings in mid-October, most major brokerages updated their views, and the $62 level represents the average of 14 current, individually attributed targets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Those targets range from $56 (TD Cowen, Hold) to $68 (Barclays, Overweight), for a mean near $62. Broader data from providers such as S&P Global shows a similar consensus in the low-$60s, with a “Strong Buy” or “Buy” tilt and no Sell ratings. The spread is notable: more cautious voices like Evercore ISI ($57) and Truist ($58) lowered targets after the quarter, while Baird’s David George raised his rating to Outperform with a $62 target, viewing the post-earnings drop as overdone.
Most firms trimmed targets by about $4 to $6 after Q3 yet kept Buy, Overweight, or Outperform ratings, treating the softness as a valuation reset rather than a fundamental break. Citi ($60), Morgan Stanley ($61), Wells Fargo ($64), and RBC Capital ($60) all adjusted lower in the October 15 revisions. This average is simply a calculation of published targets, not an official consensus, and should not be viewed as a guarantee.
At the October 28, 2026 close, BAC changed hands near $50.85, inside a 52-week range of roughly $46.12 to $65.23. Hitting $62 would therefore require a gain of about 22%—a sizable move by normal standards, even though the stock has already traded above $62 within the past year before pulling back.
The outcome hinges on whether investors re-rate the shares. Bank of America posted Q3 EPS of $0.91, down 14% year over year, after a $1.2 billion anti-money-laundering settlement charge; adjusted EPS came in closer to $1.08. Net interest income rose 8% to $16.6 billion, while trading and investment-banking fees lagged. At roughly 10 times expected 2027 earnings and a forward P/E near 11, several analysts believe the current price already reflects much of the regulatory and market uncertainty.
The clearest support is management’s own outlook. Bank of America has guided to at least 8% growth in net interest income in 2027 along with 200 to 300 basis points of positive operating leverage. Rising loan balances, improving net interest margins, and a sizable securities portfolio rolling into higher yields all back that projection. A steady U.S. economy and stable credit quality would further strengthen earnings momentum.
Valuation also plays a role: at around 10 times forward earnings, analysts such as those at Baird and Morgan Stanley argue the shares offer compensation for the regulatory overhang. Broad-based Buy ratings, a dividend yield near 2.5%, and ongoing share repurchases add further support for the price target.
The main hurdles remain execution and sentiment. The $1.2 billion settlement has placed Bank of America among large lenders facing compliance penalties, and some investors may want a wider margin of safety until controls strengthen. Continued softness in markets and investment-banking revenue—the main reasons for the Q3 shortfall—could linger if capital-markets activity slows.
A broader economic slowdown, a shift in the interest-rate outlook, or valuation compression across large-cap financials would also pressure the forecast. The stock has lagged peers and erased its 2026 gains, so restoring confidence may require several quarters rather than a quick rebound.
The most relevant technical backdrop is the 52-week range. With a low near $46 and a high near $65, the $62 target sits in the upper half of that band but below the prior peak. In short, $62 represents a recovery toward—not a breakout above—recent highs. Analysts and traders often view the $56 to $57 zone as near-term support (the lower end of the post-earnings target range and close to recent lows), while the prior high around $65 acts as resistance that would need to be reclaimed for a move toward the upper end of the target range.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms vary and no specific timing should be assumed. Investors should track Bank of America’s next quarterly results, especially any update to 2027 net interest income guidance, efficiency-ratio trends, and credit metrics. Other potential catalysts include Federal Reserve policy decisions, changes in the interest-rate environment, further regulatory developments tied to the AML settlement, and additional analyst revisions. ETF flows and sector rotation in financials are secondary but useful signals for the broader market picture.
Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. I find the tool helpful for spotting opportunities, monitoring existing positions, and catching trend shifts more efficiently than manual screening alone. For investors following BAC and other large-cap names, it provides a useful, data-driven perspective on short-term momentum that complements fundamental work.
The $62 target is simply the calculated average of current analyst price targets, not a forecast. It points to a roughly 22% move from a price near $50.85—substantial yet within the stock’s recent trading range. The bullish case rests on a return to net interest income growth in 2027, an undemanding valuation, and the fact that most analysts retained positive ratings even while lowering targets. The bearish case centers on the AML settlement, softer trading and investment-banking revenue, and the possibility of an economic or rate-driven reversal. With targets spread from $56 to $68 and real disagreement on the near-term path, the direction of Bank of America’s next earnings and guidance is likely to be the decisive factor. No outcome is assured, and the average analyst price target is a reference point, not a guarantee of future performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
BAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 37 cases where BAC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 78%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BAC's RSI Indicator exited the oversold zone, 23 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 33 of 51 cases where BAC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for BAC just turned positive on October 26, 2026. Looking at past instances where BAC's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.
Following a +0.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAC advanced for three days, in 212 of 341 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
The Aroon Indicator for BAC entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 2 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.288) is normal, around the industry mean (1.517). P/E Ratio (11.557) is within average values for comparable stocks, (11.751). Projected Growth (PEG Ratio) (0.873) is also within normal values, averaging (2.139). Dividend Yield (0.025) settles around the average of (0.034) among similar stocks. P/S Ratio (3.643) is also within normal values, averaging (3.867).
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 21, placing this stock slightly worse than average.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BAC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a major bank
Industry MajorBanks